Based on 22 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is $158.15 with a high forecast of $216.00 and a low forecast of $106.00. The average price target represents a 12.40% change from the last price of $140.70.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"88":"$88","217":"$217","120.25":"$120.3","152.5":"$152.5","184.75":"$184.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":216,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$216.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":158.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$158.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":106,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$106.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[88,120.25,152.5,184.75,217],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,140.699,146.49138461538462,152.28376923076925,158.07615384615386,163.86853846153846,169.6609230769231,175.4533076923077,181.2456923076923,187.03807692307691,192.83046153846155,198.62284615384615,204.4152307692308,210.2076153846154,{"y":216,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,140.699,142.04138461538463,143.38376923076925,144.72615384615386,146.06853846153848,147.4109230769231,148.75330769230771,150.0956923076923,151.43807692307692,152.78046153846154,154.12284615384615,155.46523076923077,156.8076153846154,{"y":158.15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,140.699,138.02984615384617,135.36069230769232,132.69153846153847,130.02238461538462,127.35323076923078,124.68407692307693,122.01492307692308,119.34576923076924,116.67661538461539,114.00746153846154,111.3383076923077,108.66915384615385,{"y":106,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":96.845,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.66,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.558,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.531,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.923,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.53,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.37,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.81,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.53,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":142.07,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.12,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.22,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.699,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$216.00

Average Price Target$158.15

Lowest Price Target$106.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Oppenheimer

xxxxxxxxxxxxx

Assigned

05/03/24

xxxxxxxxxxxxxxxxxx

J.P. Morgan

xxxxxxxxxxxxx

Reiterated

05/03/24

xxxxxxxxxxxxxxxxxx

H.C. Wainwright

xxxxxxxxxxxxx

Reiterated

05/02/24

xxxxxxxxxxxxxxxxxx

Barclays

xxxxxxxxxxxxx

Reiterated

05/02/24

xxxxxxxxxxxxxxxxxx

Guggenheim

xxxxxxxxxxxxx

Reiterated

05/02/24

xxxxxxxxxxxxxxxxxx

Canaccord Genuity

xxxxxxxxxxxxx

Reiterated

05/02/24

xxxxxxxxxxxxxxxxxx

Citi

xxxxxxxxxxxxx

Reiterated

05/02/24

xxxxxxxxxxxxxxxxxx

Goldman Sachs

xxxxxxxxxxxxx

Reiterated

05/01/24

xxxxxxxxxxxxxxxxxx

Wells Fargo

xxxxxxxxxxxxx

Reiterated

05/01/24

xxxxxxxxxxxxxxxxxx

Needham

xxxxxxxxxxxxx

Assigned

05/01/24

Evan Seigerman

BMO Capital

$129.00

Hold

-8.31%

Downside

Reiterated

05/01/24

Neurocrine Biosciences: A Balanced Hold Rating Amidst Revenue Growth and Rising Expenses

Tazeen Ahmad

Bank of America Securities

$159.00

Buy

13.01%

Upside

Reiterated

05/01/24

Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR), Moderna (NASDAQ: MRNA) and Neurocrine (NASDAQ: NBIX)

Brian Abrahams

RBC Capital

$136.00

Hold

-3.34%

Downside

Reiterated

04/29/24

RBC Capital Remains a Hold on Neurocrine (NBIX)

Akash Tewari

Jefferies

$182.00

Buy

29.35%

Upside

Reiterated

04/23/24

Jefferies Sticks to Its Buy Rating for Neurocrine (NBIX)

Marc Goodman

Leerink Partners

―

Buy

―

Reiterated

04/23/24

Buy Rating Affirmed for Neurocrine on Promising Phase 2 SAVITRI Study Results

Best Analysts Covering Neurocrine

Which Analyst Should I Follow If I Want to Buy GB:0K6R and Sell After:

1 Month

Phil NadeauTD Cowen

Success Rate

12/21 ratings generated profit

Average Return

+0.33%

reiterated a buy rating 3 months ago

Copying Phil Nadeau's trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +0.33% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Carter GouldBarclays

Success Rate

13/17 ratings generated profit

Average Return

+6.96%

reiterated a buy rating 3 days ago

Copying Carter Gould's trades and holding each position for 3 Months would result in 76.47% of your transactions generating a profit, with an average return of +6.96% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Tazeen AhmadBank of America Securities

Success Rate

17/20 ratings generated profit

Average Return

+15.47%

reiterated a buy rating 4 days ago

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 85.00% of your transactions generating a profit, with an average return of +15.47% per trade.

2 Years

Carter GouldBarclays

Success Rate

17/17 ratings generated profit

Average Return

+26.02%

reiterated a buy rating 3 days ago

Copying Carter Gould's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +26.02% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0K6R Analyst Recommendation Trends

Rating

Jan 24

Feb 24

Mar 24

Apr 24

May 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0K6R has received 28 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. 0K6R average Analyst price target in the past 3 months is $158.15.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0K6R Financial Forecast

0K6R Earnings Forecast

Next quarter’s earnings estimate for 0K6R is $1.15 with a range of $0.27 to $1.65. The previous quarter’s EPS was $0.42. 0K6R beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 37.50% of the time in the same period. In the last calendar year 0K6R has Outperformed its overall industry.

0K6R Sales Forecast

Next quarter’s sales forecast for 0K6R is $547.02M with a range of $529.92M to $581.00M. The previous quarter’s sales results were $515.30M. 0K6R beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 45.95% of the time in the same period. In the last calendar year 0K6R has Outperformed its overall industry.

0K6R Stock Forecast FAQ

What is GB:0K6R’s average 12-month price target, according to analysts?

Based on analyst ratings, Neurocrine’s 12-month average price target is $158.15.

What is GB:0K6R’s upside potential, based on the analysts’ average price target?

Neurocrine has 12.40% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Neurocrine a Buy, Sell or Hold?

Neurocrine has a conensus rating of Moderate Buy, which is based on 16 buy ratings, 6 hold ratings and 0 sell ratings.

What is Neurocrine’s share price target?

The average share price target for Neurocrine is $158.15. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $216.00 ,and the lowest forecast is $106.00. The average share price target represents 12.40% Increase from the current price of $140.699.

What do analysts say about Neurocrine?

Neurocrine’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of Neurocrine?

To buy shares of GB:0K6R, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Neurocrine (0K6R) Share Forecast & Price Target

0K6R Analyst Ratings

0K6R Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Neurocrine

0K6R Analyst Recommendation Trends

0K6R Financial Forecast

0K6R Earnings Forecast

0K6R Sales Forecast

0K6R Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts